From an advertisement by AmGen in Cardiology News August 2015:
New therapy for high LDL level.
PCSK9 inhibitor
PCSK9 (Proprotein convertase subtilisin/kexin type 9) degrades LDL receptors in hepatocytes.
Injection Praluent (Alirocumab) 75 mg or 150 mg. self-administer, q2weeks, recently approved by FDA.
No comments:
Post a Comment